CN Patent

CN101808988A — 用于肿瘤治疗的哌啶和哌嗪衍生物

Assigned to Merck Patent GmbH · Expires 2010-08-18 · 16y expired

What this patent protects

式(I)化合物，其中R 1 、R 2 、R 3 、D、G、Q和W具有与权利要求1所述的相同的含义，其可以并用于治疗肿瘤。

USPTO Abstract

式(I)化合物，其中R 1 、R 2 、R 3 、D、G、Q和W具有与权利要求1所述的相同的含义，其可以并用于治疗肿瘤。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN101808988A
Jurisdiction: CN
Classification: —
Expires: 2010-08-18
Drug substance claim: No
Drug product claim: No
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.